T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Cell-based therapy holds great potential to address unmet medical needs and revolutionize
the healthcare industry, as demonstrated by several therapeutics such as CAR-T cell …

Natural killer (NK) cells are a critical component of the innate immune system. Chimeric
antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding …

Cell-based drug delivery systems (DDSs) have received attention recently because of their
unique biological properties and self-powered functions, such as excellent biocompatibility …

In recent years, tremendous advancements in nanomedicine have resulted in the rapid
development of various nanoformulations, especially the treatment of solid tumors. Despite …

Living cell‐based drug delivery systems (LC‐DDSs) are limited by adverse interactions
between drugs and carrier cells, typically drug‐induced toxicity to carrier cells and restriction …

Cancer immunotherapy has achieved remarkable clinical efficacy through recent advances
such as chimeric antigen receptor‐T cell (CAR‐T) therapy, immune checkpoint blockade …

Natural Killer (NK) cells are critical members of the innate immunity lymphocytes and have a
critical role in host defense against malignant cells. Adoptive cell therapy (ACT) using …

Immunotherapy continues to be in the spotlight of oncology therapy research in the past few
years and has been proven to be a promising option to modulate one's innate and adaptive …

Metastasis is the major cause of cancer-related deaths. Invasive primary cancers often
metastasize after circulating tumor cells (CTCs) enter the bloodstream or lymph node to …